Arcutis Biotherapeutics recently reported positive topline results from its INTEGUMENT-INFANT Phase 2 trial, showing that ZORYVE cream 0.05% improved disease severity and was well tolerated in 101 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results